Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
Teresa Battista,Massimiliano Scalvenzi,Fabrizio Martora,Luca Potestio,Matteo Megna
DOI: https://doi.org/10.2147/CCID.S417679
2023-07-25
Abstract:Teresa Battista, Massimiliano Scalvenzi, &ast Fabrizio Martora, &ast Luca Potestio, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy &astThese authors contributed equally to this work Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 - 81 – 7462457, Fax +39 - 81 – 7462442, Email Background: Nail psoriasis (NP) has a prevalence that ranges from 10 to 82% among patients with psoriasis (PsO) and is one of the most common difficult to treat site of psoriasis. We performed a thorough review of the literature, exploring evidence regarding all available NP systemic treatments, describing also in detail NP dedicated clinical trials. Methods: A literature search was conducted in PubMed and Embase prior to February 2023 using a combination of the terms "nail" AND "psoriasis" AND "systemic therapy" AND/OR "systemic treatment". A total of 47 original studies and case reports were reviewed in this article. Results: Systemic therapies should be considered when the disorder involves more than 3 nails, has extensive skin and joint involvement, and has a significant impact on QoL, due to their best long-term efficacy. In detail, conventional and biologic systemic drugs demonstrated efficacy in recent trials, including acitretin, methotrexate, cyclosporine, apremilast, adalimumab, infliximab, etanercept, certolizumab, golimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab and tildrakizumab. Conclusion: Several therapies have demonstrated efficacy and safety in the treatment of NP; however, the choice of treatment depends not only on the severity of the nail involvement, but also on whether PsA is present, the patient's comorbidities other than PsA, previous treatment history, and the patient's drug preferences. Keywords: nail psoriasis, psoriasis, treatment, biologics Nail psoriasis (NP) has a prevalence that ranges from 10 to 82% among patients with psoriasis (PsO) and is one of the most common difficult to treat site of psoriasis. 1 In 5–10% of cases, NP manifests in the absence of cutaneous symptoms. 2 NP can be associated with pain, cosmetic concerns, and impaired finger function that can significantly impact the patient's quality of life (QoL). 3,4 Studies have reported that psoriasis patients with nail involvement have reduced compared to psoriasis patients without nail involvement. 5 NP presents a heterogeneous clinical spectrum, depending on the part of the affected nail structure, which can be divided into nail matrix (pitting, leukonychia, red spots in the lunula, nail plate crumbling, onychomadesis and Beau lines) or nail bed (salmon patches, onycholysis, nail bed hyperkeratosis, and splinter hemorrhage) alterations. 6,7 Moreover, the nail structure presents therapeutic challenges, such as poor penetration of topical treatments across the nail plate and pain associated with the use of intralesional therapies. 7,8 NP is also an independent prognostic factor for comorbidities such as psoriatic arthritis (PsA) and greater degrees of skin severity in plaque psoriasis. 9 Nails are strongly anchored to the musculoskeletal system and are therefore functionally linked to it. It is believed that given the link between the extensor tendon and the nail matrix, inflammation of this structure may play a key role in nail pitting in both PsA and psoriasis, supporting a strong significant higher risk of PsA in NP subjects. 10 There are several different scoring systems for NP severity, including the Nail Psoriasis Severity Index (NAPSI), mNAPSI (Modified Nail Psoriasis Severity Index), and PNSS (Psoriasis Nail Severity Score). 11 NP is one of the most challenging areas to treat for the factors above explored, and it deserves a prompt treatment due to increased PsA risk as well as limitations in patients' everyday life. Topical and injectable therapies are recommended for NP with few nails involved. Systemic therapies, including biologics, can be considered for patients with multiple and resistant nail disease, impaired QoL, and severe skin and joint involvement. 7 In recent years, substantial progress has been made in understanding the pathogenesis of psoriatic skin and joint disease, and several highly effective therapies are now available for the treatment of moderate to severe disease. However, NP studies have been more limited, possibly leading to the undertreatment of NP, which is a significant unmet need in the management of psoriatic disease.<su -Abstract Truncated-
dermatology